|
1
|
Hong QY, Wu GM, Qian GS, Hu CP, Zhou JY,
Chen LA, Li WM, Li SY, Wang K, Wang Q, et al: Prevention and
management of lung cancer in China. Cancer. 121(Suppl 17):
S3080–S3088. 2015. View Article : Google Scholar
|
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi Y, Sun Y, Ding C, Wang Z, Wang C, Wang
Z, Bai C, Bai C, Feng J, Liu X, et al: China experts consensus on
icotinib for non-small cell lung cancer treatment (2015 version). J
Thorac Dis. 7:E468–E472. 2015.PubMed/NCBI
|
|
4
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar
|
|
5
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg
JF: Mutations in the EGFR kinase domain mediate STAT3 activation
via IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bournazou E and Bromberg J: Targeting the
tumor microenvironment: JAK-STAT3 signaling. JAKSTAT.
2:e238282013.PubMed/NCBI
|
|
8
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li CJ, Li YC, Zhang DR and Pan JH: Signal
transducers and activators of transcription 3 function in lung
cancer. J Cancer Res Ther. 9(Suppl 2): S67–S73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grivennikov SI and Karin M: Dangerous
liaisons: STAT3 and NF-kappa B collaboration and crosstalk in
cancer. Cytokine Growth Factor Rev. 21:11–19. 2010. View Article : Google Scholar
|
|
11
|
Brown JM and Wilson G: Apoptosis genes and
resistance to cancer therapy: What does the experimental and
clinical data tell us? Cancer Biol Ther. 2:477–790. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barré B, Vigneron A, Perkins N, Roninson
IB, Gamelin E and Coqueret O: The STAT3 oncogene as a predictive
marker of drug resistance. Trends Mol Med. 13:4–11. 2007.
View Article : Google Scholar
|
|
13
|
Yan X, Li P, Zhan Y, Qi M, Liu J, An Z,
Yang W, Xiao H, Wu H, Qi Y and Shao H: Dihydroartemisinin
suppresses STAT3 signaling and Mcl-1 and Survivin expression to
potentiate ABT-263-induced apoptosis in non-small cell lung cancer
cells harboring EGFR or RAS mutation. Biochem Pharmacol. 150:72–85.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu YH and Lu S: A meta-analysis of STAT3
and phospho-STAT3 expression and survival of patients with
non-small-cell lung cancer. Eur J Surg Oncol. 40:311–317. 2014.
View Article : Google Scholar
|
|
15
|
Mishra BB and Tiwari VK: Natural products:
An evolving role in future drug discovery. Eur J Med Chem.
46:4769–4807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu L, Xiong X, Shen M, Ru D, Gao P, Zhang
X, Huang C, Sun Y, Li H and Duan Y: Co-delivery of triptolide and
curcumin for ovarian cancer targeting therapy via mPEG-DPPE/CaP
nanoparticle. J Biomed Nanotechnol. 14:1761–1772. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Klauber-DeMore N, Schulte BA and Wang GY:
Targeting MYC for triple-negative breast cancer treatment.
Oncoscience. 5:120–121. 2018.PubMed/NCBI
|
|
18
|
Li SG, Shi QW, Yuan LY, Qin LP, Wang Y,
Miao YQ, Chen Z, Ling CQ and Qin WX: C-Myc-dependent repression of
two oncogenic miRNA clusters contributes to triptolide-induced cell
death in hepatocellular carcinoma cells. J Exp Clin Cancer Res.
37:512018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao X, Tong J and Wang Y, Zhu Z, Yin Y and
Wang Y: Triptolide exhibits antitumor effects by reversing
hypermethylation of WIF1 in lung cancer cells. Mol Med Rep.
18:3041–3049. 2018.PubMed/NCBI
|
|
20
|
Hou ZY, Tong XP, Peng YB, Zhang BK and Yan
M: Broad targeting of triptolide to resistance and sensitization
for cancer therapy. Biomed Pharmacother. 104:771–780. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Beglyarova N, Banina E, Zhou Y,
Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N,
Gabitova L, Restifo D, et al: Screening of conditionally
reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC
interactions as a target in pancreatic cancer. Clin Cancer Res.
22:6153–6163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meng C, Zhu H, Song H, Wang Z, Huang G, Li
D, Ma Z and Ma J, Qin Q, Sun X and Ma J: Targets and molecular
mechanisms of triptolide in cancer therapy. Chin J Cancer Res.
26:622–626. 2014.PubMed/NCBI
|
|
23
|
Chang L, Lei X, Qin YU, Zhang X, Jin H,
Wang C, Wang X, Li G, Tan C and Su J: MicroRNA-133b inhibits cell
migration and invasion by targeting matrix metalloproteinase 14 in
glioblastoma. Oncol Lett. 10:2781–2786. 2015. View Article : Google Scholar
|
|
24
|
Li Z, Jiao X, Wang C, Shirley LA, Elsaleh
H, Dahl O, Wang M, Soutoglou E, Knudsen ES and Pestell RG:
Alternative cyclin D1 splice forms differentially regulate the DNA
damage response. Cancer Res. 70:8802–8811. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lamb J, Ramaswamy S, Ford HL, Contreras B,
Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR and Ewen
ME: A mechanism of cyclin D1 action encoded in the patterns of gene
expression in human cancer. Cell. 114:323–334. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dremina ES, Sharov VS and Schöneich C:
Heat-shock proteins attenuate SERCA inactivation by the
anti-apoptotic protein Bcl-2: Possible implications for the ER
Ca2+-mediated apoptosis. Biochem J. 444:127–139. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duan S, Tsai Y, Keng P and Chen Y, Lee SO
and Chen Y: IL-6 signaling contributes to cisplatin resistance in
non-small cell lung cancer via the up-regulation of anti-apoptotic
and DNA repair associated molecules. Oncotarget. 6:27651–27660.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ham IH, Oh HJ, Jin H, Bae CA, Jeon SM,
Choi KS, Son SY, Han SU, Brekken RA, Lee D and Hur H: Targeting
interleukin-6 as a strategy to overcome stroma-induced resistance
to chemotherapy in gastric cancer. Mol Cancer. 18:682019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sharma SB and Gupta R: Drug development
from natural resource: A systematic approach. Mini Rev Med Chem.
15:52–57. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yan P and Sun X: Triptolide: A new star
for treating human malignancies. J Cancer Res Ther. 14(Suppl):
S271–S275. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang N, Dong XP, Zhang SL, You QY, Jiang
XT and Zhao XG: Triptolide reverses the Taxol resistance of lung
adenocarcinoma by inhibiting the NF-κB signaling pathway and the
expression of NF-κB-regulated drug-resistant genes. Mol Med Rep.
13:153–159. 2016. View Article : Google Scholar
|
|
32
|
Teng F, Xu Z, Chen J, Zheng G, Zheng G, Lv
H, Wang Y, Wang L and Cheng X: DUSP1 induces apatinib resistance by
activating the MAPK pathway in gastric cancer. Oncol Rep.
40:1203–1222. 2018.PubMed/NCBI
|
|
33
|
Li X, Lu Q, Xie W, Wang Y and Wang G:
Anti-tumor effects of triptolide on angiogenesis and cell apoptosis
in osteosarcoma cells by inducing autophagy via repressing
Wnt/β-catenin signaling. Biochem Biophys Res Commun. 496:443–449.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fan D, He X, Bian Y, Guo Q, Zheng K, Zhao
Y, Lu C, Liu B, Xu X, Zhang G and Lu A: Triptolide modulates TREM-1
signal pathway to inhibit the inflammatory response in rheumatoid
arthritis. Int J Mol Sci. 17:4982016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen J, Gao J, Yang J, Zhang Y and Wang L:
Effect of triptolide on the regulation of ATP-binding cassette
transporter A1 expression in lipopolysaccharide-induced acute lung
injury of rats. Mol Med Rep. 10:3015–3020. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vispé S, DeVries L, Créancier L, Besse J,
Bréand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet
C, et al: Triptolide is an inhibitor of RNA polymerase I and
II-dependent transcription leading predominantly to down-regulation
of short-lived mRNA. Mol Cancer Ther. 8:2780–2790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Z, Jin H, Xu R, Mei Q and Fan D:
Triptolide downregulates Rac1 and the JAK/STAT3 pathway and
inhibits colitis-related colon cancer progression. Exp Mol Med.
41:717–727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma J, Zhao Z, Wu K, Xu Z and Liu K: MCL-1
is the key target of adjuvant chemotherapy to reverse the
cisplatin-resistance in NSCLC. Gene. 587:147–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oliveira A, Beyer G, Chugh R, Skube SJ,
Majumder K, Banerjee S, Sangwan V, Li L, Dawra R, Subramanian S, et
al: Triptolide abrogates growth of colon cancer and induces cell
cycle arrest by inhibiting transcriptional activation of E2F. Lab
Invest. 95:648–659. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Biliran H Jr, Wang Y, Banerjee S, Xu H,
Heng H, Thakur A, Bollig A, Sarkar FH and Liao JD: Overexpression
of cyclin D1 promotes tumor cell growth and confers resistance to
cispl-atin-mediated apoptosis in an elastase-myc
transgene-expressing pancreatic tumor cell line. Clin Cancer Res.
11:6075–6086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aggarwal P, Vaites LP, Kim JK, Mellert H,
Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB and
Diehl JA: Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression
and triggers neoplastic growth via activation of the PRMT5
methyltransferase. Cancer Cell. 18:329–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shields BJ, Hauser C, Bukczynska PE, Court
NW and Tiganis T: DNA replication stalling attenuates tyrosine
kinase signaling to suppress S phase progression. Cancer Cell.
14:166–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jirawatnotai S, Hu Y, Michowski W, Elias
JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB,
et al: A function for cyclin D1 in DNA repair uncovered by protein
interactome analyses in human cancers. Nature. 474:230–234. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yao Z, Fenoglio S, Gao DC, Camiolo M,
Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V,
et al: TGF-beta IL-6 axis mediates selective and adaptive
mechanisms of resistance to molecular targeted therapy in lung
cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang S, Long S, Xiao S, Wu W and Hann SS:
Decoction of chinese herbal medicine fuzheng kang-ai induces lung
cancer cell apoptosis via STAT3/Bcl-2/caspase-3 pathway. Evid Based
Complement Alternat Med. 2018:85679052018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yu H and Jove R: The stats of cancer-new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dechow TN, Pedranzini L, Leitch A, Leslie
K, Gerald WL, Linkov I and Bromberg JF: Requirement of matrix
metallopro-teinase-9 for the transformation of human mammary
epithelial cells by Stat3-C. Proc Natl Acad Sci USA.
101:10602–10607. 2004. View Article : Google Scholar
|
|
48
|
El-Badrawy MK, Yousef AM, Shaalan D and
Elsamanoudy AZ: Matrix metalloproteinase-9 expression in lung
cancer patients and its relation to serum mmp-9 activity,
pathologic type, and prognosis. J Bronchology Interv Pulmonol.
21:327–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Backstrom JR and Tökés ZA: The 84-kDa form
of human matrix metalloproteinase-9 degrades substance P and
gelatin. J Neurochem. 64:1312–1318. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ao N and Liu Y, Bian X, Feng H and Liu Y:
Ubiquitin-specific peptidase 22 inhibits colon cancer cell invasion
by suppressing the signal transducer and activator of transcription
3/matrix metalloproteinase 9 pathway. Mol Med Rep. 12:2107–2113.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim JH and Park B: Triptolide blocks the
STAT3 signaling pathway through induction of protein tyrosine
phosphatase SHP-1 in multiple myeloma cells. Int J Mol Med.
40:1566–1572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Niu F, Li Y, Lai FF, Ni L, Ji M, Jin J,
Yang HZ, Wang C, Zhang DM and Chen XG: LB-1 exerts antitumor
activity in pancreatic cancer by inhibiting HIF-1α and Stat3
signaling. J Cell Physiol. 230:2212–2223. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F,
Ha SJ, Soo RA, Christensen JG, Lee JH and Cho BC: Activation of
IL-6R/JAK1/STAT3 signaling induces de novo resistance to
irreversible EGFR inhibitors in non-small cell lung cancer with
T790M resistance mutation. Mol Cancer Ther. 11:2254–2264. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Maji S, Shriwas O, Samal SK, Priyadarshini
M, Rath R, Panda S, Das Majumdar SK, Muduly DK and Dash R: STAT3-
and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in
oral squamous cell carcinoma. Carcinogenesis. 40:173–183. 2019.
View Article : Google Scholar
|
